5 Best Vaccine Stocks to Buy Now

3. Pfizer Inc. (NYSE: PFE)

Number of Hedge Fund Holders: 63

Pfizer Inc. (NYSE: PFE) is a US-based drug giant. Pfizer was one of the first companies to publicly market the coronavirus vaccine and the company has since partnered with many country governments for the supply of the vaccine. The company has a market cap of well over $200 billion and an annual revenue that exceeds $40 billion. The company’s shares are set to rise further as the US government ramps up vaccine production with the aim of vaccinating all adult US population. According to news media reports, the US is administering more than 3 million vaccine doses daily. 

Since vaccinating children is one of the foremost challenges in order to get life back to normal across the world, the company has released a study detailing that the vaccine it produces is highly effective for children aged between 12 and 14 years. The study is short in scope, and British firm AstraZeneca has promised a large clinical trial for its vaccine which will begin soon. Past vaccine trials have tended to concentrate on older patients since that age group was the most vulnerable to the coronavirus.